Remove tag all-us
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

Focal onset seizure is a type of epilepsy in which seizures start in one side of the brain, acconting for around 60% of all epilepsy cases. “We look forward to the full technology appraisal guidance (TAG) which is due to be published in early December 2021,” he added.

article thumbnail

Scientists and medics turn to TikTok to reassure public on vaccine safety

pharmaphorum

TikTok itself meanwhile says it has taken steps to make sure its users have access to reliable information about the pandemic, which will be stepped up as immunisation programmes start in the UK, US and elsewhere.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

Amgen could be the winner of a high-stakes patent spat with Sanofi as tensions run high weeks before the March 27 US Supreme Court hearing. Both drugs come with a high price tag. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US.

104
104
article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

“Digitally native brands are typically agile businesses from the ground up, and agility and flexibility are part of their core makeup,” says Joe Holmes, vice president, marketing services, US at Tag. We’re all trying to find ways to automate. Jeremy Richter, Tag. Build on the rapid responses to COVID-19.

article thumbnail

Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development

Pharmaceutical Technology

On January 12, Versanis Bio announced that enrollment had begun for its Phase IIb trial, BELIEVE (NCT05616013), which aims to study bimagrumab’s (BYM-338) efficacy and safety in the US, among other locations. Mounjaro is anticipated to launch in the US later this year or by early 2024.

article thumbnail

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

pharmaphorum

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. The European population is meanwhile estimated at several thousand patients, across all stages, according to registry data.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. That’s obviously a challenge that’s relevant to all industries. “As Virtual connections.